Management Change/Compensation (Form 8-K)

Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 26, 2026, the Board of Directors (the "Board") of OSR Holdings, Inc. (the "Company") approved the appointment of Yeiseok Kim as Chief Operating Officer of the Company, effective April 16, 2026.

Mr. Kim, age 36, most recently served as a Senior Analyst at OSR Holdings Co., Ltd., a subsidiary of the Company, from 2020 to 2025, where he supported the Company and its subsidiaries' cross-border healthcare investments and pharmaceutical licensing activities. Prior to joining the Company, Mr. Kim obtained his Korean medical license in 2019. Mr. Kim received a BA in Environmental Science from Seoul National University in 2013 and an MS in Medicine from the Graduate School of Medicine at Jeonbuk National University in 2019. Mr. Kim is well qualified as Chief Operating Officer of the Company because of his medical expertise and experience in cross-border healthcare investment and pharmaceutical licensing.

In connection with his appointment as Chief Operating Officer, OSR Holdings Co., Ltd. entered into an amended employment agreement with Mr. Kim, pursuant to which he serves as Chief Operating Officer of the Company, which reflects an increase in his annual compensation. Under such arrangement, Mr. Kim will receive:

There are no arrangements or understandings between Mr. Kim and any other person pursuant to which he was appointed as Chief Operating Officer. There are no family relationships between Mr. Kim and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.